A Review of Abiraterone Acetate for the Treatment of Metastatic Castration-Resistant Prostate Cancer  

作　　者：Lin Ma 

机构地区：[1]Zhangjiakou First Hospital,Zhangjiakou 075000,Hebei Province,China

出　　处：《Journal of Clinical and Nursing Research》2024年第6期311-315,共5页临床护理研究（英文）

摘　　要：Prostate cancer is a common malignant tumor of the urinary system in men,and the incidence and detection rate of prostate cancer have been rising significantly in recent years.Androgens play an important role in the occurrence and development of prostate cancer,so hormone deprivation therapy has become an essential means of prostate cancer treatment.Abiraterone acetate is a therapeutic agent for prostate cancer by inhibiting the enzyme activity of CYP17,thereby blocking androgen biosynthesis.In this paper,we present a review of the current mechanism of action of abiraterone acetate for prostate cancer treatment,research progress,and its side effects and limitations.It is expected to provide help for further research on the treatment of prostate cancer.

关 键 词：Abiraterone acetate Prostate cancer INDICATIONS Treatment program 

分 类 号：R73[医药卫生—肿瘤]